HCA Healthcare appoints former Subway CEO John Chidsey to board

Published 11/07/2025, 13:38
HCA Healthcare appoints former Subway CEO John Chidsey to board

NASHVILLE - HCA Healthcare, Inc. (NYSE:HCA), a healthcare provider with an impressive market capitalization of $91 billion and a "GREAT" financial health score according to InvestingPro, announced Thursday the appointment of John W. Chidsey, III as an independent director effective July 15, 2025, expanding its board from nine to ten members.

Chidsey, who most recently served as global chief executive officer of Subway, will join HCA Healthcare’s audit and compliance committee, compensation committee, and patient safety and quality of care committee.

Prior to his role at Subway, Chidsey held the position of chief executive officer at Burger King Holdings, Inc. and various leadership roles at Cendant Corporation and PepsiCo.

"John Chidsey’s distinguished career demonstrates his extensive experience in leading corporate strategy at large, complex public and private companies," said Thomas F. Frist III, chairman of the board of HCA Healthcare, in a press release statement.

Chidsey currently serves on the board of Norwegian Cruise Line Holdings Ltd. and previously held board positions at Encompass Health Corporation, Burger King Holdings, Inc. (as chairman), and Brinker International, Inc.

He holds a bachelor’s degree from Davidson College, along with MBA and J.D. degrees from Emory University.

HCA Healthcare operates 192 hospitals and approximately 2,500 ambulatory sites of care across 20 states and the United Kingdom. Founded in 1968, the Nashville-based healthcare provider employs its approximately 44 million annual patient encounters to advance medical science and improve patient care. The company has demonstrated strong financial performance with annual revenue of $71.6 billion and EBITDA of $14.2 billion. InvestingPro analysis reveals 8 additional key insights about HCA’s performance and outlook, available to subscribers.

In other recent news, HCA Healthcare has maintained its Overweight rating from Cantor Fitzgerald, with a price target of $444. Cantor Fitzgerald highlighted potential revenue growth from Tennessee’s Directed Payment Program, which could add significant basis points to inpatient revenue per admission. RBC Capital has also increased its price target for HCA Healthcare to $404, reflecting confidence in the company’s positioning amid healthcare policy changes. Meetings with HCA management revealed insights into the company’s resiliency program and artificial intelligence initiatives, contributing to RBC’s positive outlook. Additionally, Cantor Fitzgerald noted proposed changes to provider tax regulations that might impact hospital operators, including HCA Healthcare, but suggested the actual impact may be less severe than initially anticipated. The firm also pointed to HCA’s partnership with Galen College of Nursing as a strategic move to address nurse staffing needs, potentially providing a competitive advantage. These developments indicate a focus on strategic growth and adaptation to policy changes, as noted by the analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.